GNFT vs. AUTL, HUMA, IMTX, MESO, INBX, RLAY, PROK, PRME, SRRK, and CRGX
Should you be buying Genfit stock or one of its competitors? The main competitors of Genfit include Autolus Therapeutics (AUTL), Humacyte (HUMA), Immatics (IMTX), Mesoblast (MESO), Inhibrx (INBX), Relay Therapeutics (RLAY), ProKidney (PROK), Prime Medicine (PRME), Scholar Rock (SRRK), and CARGO Therapeutics (CRGX). These companies are all part of the "biological products, except diagnostic" industry.
Autolus Therapeutics (NASDAQ:AUTL) and Genfit (NASDAQ:GNFT) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their community ranking, risk, profitability, institutional ownership, earnings, valuation, media sentiment, dividends and analyst recommendations.
Genfit has higher revenue and earnings than Autolus Therapeutics.
In the previous week, Autolus Therapeutics had 1 more articles in the media than Genfit. MarketBeat recorded 3 mentions for Autolus Therapeutics and 2 mentions for Genfit. Autolus Therapeutics' average media sentiment score of 0.94 beat Genfit's score of 0.72 indicating that Genfit is being referred to more favorably in the news media.
72.8% of Autolus Therapeutics shares are held by institutional investors. Comparatively, 2.2% of Genfit shares are held by institutional investors. 25.7% of Autolus Therapeutics shares are held by company insiders. Comparatively, 4.2% of Genfit shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Autolus Therapeutics received 155 more outperform votes than Genfit when rated by MarketBeat users. However, 68.09% of users gave Genfit an outperform vote while only 67.18% of users gave Autolus Therapeutics an outperform vote.
Autolus Therapeutics' return on equity of 0.00% beat Genfit's return on equity.
Autolus Therapeutics presently has a consensus target price of $8.70, indicating a potential upside of 107.64%. Genfit has a consensus target price of $11.00, indicating a potential upside of 112.36%. Given Autolus Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Genfit is more favorable than Autolus Therapeutics.
Autolus Therapeutics has a beta of 2.03, suggesting that its stock price is 103% more volatile than the S&P 500. Comparatively, Genfit has a beta of 1.06, suggesting that its stock price is 6% more volatile than the S&P 500.
Summary
Genfit beats Autolus Therapeutics on 8 of the 15 factors compared between the two stocks.
Get Genfit News Delivered to You Automatically
Sign up to receive the latest news and ratings for GNFT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GNFT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
